In vitro release of biologically active adriamycin by magnetically responsive albumin microspheres.
The kinetic release of therapeutically active Adriamycin from two different heat-stabilized preparations of magnetically responsive albumin microspheres (1 micron) has been evaluated using a rapid in vitro bioassay-harvesting system. Release products are added to freshly plated monolayers of a malignant Fisher 344 rat fibrosarcoma cell line, and the inhibition of [3H]uridine incorporation into trichloroacetic acid-precipitable material (RNA) and whole cells is determined in a 6-hr microtiter assay. The latter harvesting technique utilizes semiautomated cell collection using a multiple sample harvester. Standard fluorometric drug analyses are used to quantitate the chemical release rates of Adriamycin and related degradation products (aglycones). By altering the temperature of albumin matrix stabilization from 22 to 135 degrees, the half-time for the release of therapeutically active drug has been varied from 15 min to 9 hr. The biological activity of drug products released by the highest temperature (135 degrees) preparation is 78% of that for the native free drug. These in vitro antitumor assays are used to predict the maximal rates of release that could occur at the tissue level under optimal conditions of in vivo targeting.
D000418:Albumins; D000818:Animals; D001681:Biological Assay / Q000379:methods*; D002460:Cell Line; D003692:Delayed-Action Preparations; D004317:Doxorubicin / Q000494:pharmacology; D005069:Evaluation Studies as Topic; D006207:Half-Life; D008280:Magnetics; D008863:Microspheres; D012334:RNA, Neoplasm / Q000378:metabolism; D051381:Rats
D000418:Albumins; D003692:Delayed-Action Preparations; D012334:RNA, Neoplasm; D004317:Doxorubicin